Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells

Karthika, Chenmala; Sureshkumar, Raman; Zehravi, Mehrukh; Akter, Rokeya; Ali, Faraat; Ramproshad, Sarker; Mondal, Banani; Dey, Abhijit; Rahman, Habibur; Antonescu, Angela; Cavalu, Simona

doi:10.3390/life12060811

Cited by 20 publications

(7 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If and when such data becomes available, it will help with proper case management (Ezeokoli and Pohl 2020 ). Fungal infections can make COVID-19 diagnosis, treatment, and development more challenging, whether they occur before or after COVID-19 exposure (Karthika et al 2022b ; Chaung et al 2020 ; Kim et al 2020 ; Ding et al 2020 ; Gangneux et al 2020 ). Pre-existing fungal infections are uncommon at this period.…”

Section: Epidemiology Of Fungal Coinfections In Covid-19 Patientsmentioning

confidence: 99%

The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance

Islam

Rahman

Ahasan

et al. 2022

Environ Sci Pollut Res

Self Cite

View full text Add to dashboard Cite

The emergence of various diseases during the COVID-19 pandemic made health workers more attentive, and one of the new pathogens is the black fungus (mucormycosis). As a result, millions of lives have already been lost. As a result of the mutation, the virus is constantly changing its traits, including the rate of disease transmission, virulence, pathogenesis, and clinical signs. A recent analysis revealed that some COVID-19 patients were also coinfected with a fungal disease called mucormycosis (black fungus). India has already categorized the COVID-19 patient black fungus outbreak as an epidemic. Only a few reports are observed in other countries. The immune system is weakened by COVID-19 medication, rendering it more prone to illnesses like black fungus (mucormycosis). COVID-19, which is caused by a B.1.617 strain of the SARS-CoV-2 virus, has been circulating in India since April 2021. Mucormycosis is a rare fungal infection induced by exposure to a fungus called mucormycete. The most typically implicated genera are Mucor rhyzuprhizopusdia and Cunninghamella . Mucormycosis is also known as zygomycosis. The main causes of infection are soil, dumping sites, ancient building walls, and other sources of infection (reservoir words “mucormycosis” and “zygomycosis” are occasionally interchanged). Zygomycota, on the other hand, has been identified as polyphyletic and is not currently included in fungal classification systems; also, zygomycosis includes Entomophthorales, but mucormycosis does not. This current review will be focused on the etiology and virulence factors of COVID-19/mucormycosis coinfections in COVID-19-associated mucormycosis patients, as well as their prevalence, diagnosis, and treatment. Graphical abstract

show abstract

Section: Epidemiology Of Fungal Coinfections In Covid-19 Patientsmentioning

confidence: 99%

The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance

Islam

Rahman

Ahasan

et al. 2022

Environ Sci Pollut Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, low drug release may bring about high toxicity at local delivery sites [ 94 ]. Another major barrier against the efficacy of anticancer treatment is MDR [ 95 ]. Inherent resistance to chemotherapy drugs exists in certain cancer cells, while others acquire this trait through mutations during the carcinogenesis process [ 96 ].…”

Section: New Approaches In Cancer Therapymentioning

confidence: 99%

New insights into targeted therapy of glioblastoma using smart nanoparticles

Ghaznavi,

Afzalipour,

Khoei

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense promise for revolutionizing diagnostic and therapeutic approaches in the field of cancer. This innovative fusion of biology, medicine, and nanotechnology aims to create diagnostic and therapeutic agents with enhanced safety and efficacy, particularly in the realm of theranostics for various malignancies. Diverse inorganic, organic, and hybrid organic–inorganic nanoparticles, each possessing unique properties, have been introduced into this domain. This review seeks to highlight the latest strides in targeted glioblastoma therapy by focusing on the application of inorganic smart nanoparticles. Beyond exploring the general role of nanotechnology in medical applications, this review delves into groundbreaking strategies for glioblastoma treatment, showcasing the potential of smart nanoparticles through in vitro studies, in vivo investigations, and ongoing clinical trials.

show abstract

“…As a result, P-gp efflux is a vital step to overcome for successful therapy and drug development. Modifying P-gp function using various inducers, inhibitors, or genetic polymorphisms is a common strategy [110].…”

Section: Authors' Perspectivementioning

confidence: 99%

Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein

Karthika

Sureshkumar

Zehravi

et al. 2022

Life

Self Cite

View full text Add to dashboard Cite

P-glycoprotein (P-gp) is a major factor in the multidrug resistance phenotype in cancer cells. P-gp is a protein that regulates the ATP-dependent efflux of a wide range of anticancer medicines and confers resistance. Due to its wide specificity, several attempts have been made to block the action of P-gp to restore the efficacy of anticancer drugs. The major goal has been to create molecules that either compete with anticancer medicines for transport or function as a direct P-gp inhibitor. Despite significant in vitro success, there are presently no drugs available in the clinic that can “block” P-gp–mediated resistance. Toxicity, unfavourable pharmacological interactions, and a variety of pharmacokinetic difficulties might all be the reason for the failure. On the other hand, P-gp has a significant effect in the body. It protects the vital organs from the entry of foreign bodies and other toxic chemicals. Hence, the inhibitors of P-gp should not hinder its action in the normal cells. To develop an effective inhibitor of P-gp, thorough background knowledge is needed in this field. The main aim of this review article was to set forth the merits and demerits of the action of P-gp on cancer cells as well as on normal cells. The influence of P-gp on cancer drug delivery and the contribution of P-gp to activating drug resistance were also mentioned.

show abstract

Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells

Cited by 20 publications

References 91 publications

The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance

The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance

New insights into targeted therapy of glioblastoma using smart nanoparticles

Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein

Contact Info

Product

Resources

About